315 related articles for article (PubMed ID: 23100465)
1. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies.
Alain T; Morita M; Fonseca BD; Yanagiya A; Siddiqui N; Bhat M; Zammit D; Marcus V; Metrakos P; Voyer LA; Gandin V; Liu Y; Topisirovic I; Sonenberg N
Cancer Res; 2012 Dec; 72(24):6468-76. PubMed ID: 23100465
[TBL] [Abstract][Full Text] [Related]
2. Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis.
Zakaria C; Sean P; Hoang HD; Leroux LP; Watson M; Workenhe ST; Hearnden J; Pearl D; Truong VT; Robichaud N; Yanagiya A; Tahmasebi S; Jafarnejad SM; Jia JJ; Pelin A; Diallo JS; Le Boeuf F; Bell JC; Mossman KL; Graber TE; Jaramillo M; Sonenberg N; Alain T
PLoS Pathog; 2018 Aug; 14(8):e1007264. PubMed ID: 30138450
[TBL] [Abstract][Full Text] [Related]
3. The effect of p-4E-BP1 and p-eIF4E on cell proliferation in a breast cancer model.
Pons B; Peg V; Vázquez-Sánchez MA; López-Vicente L; Argelaguet E; Coch L; Martínez A; Hernández-Losa J; Armengol G; Ramon Y Cajal S
Int J Oncol; 2011 Nov; 39(5):1337-45. PubMed ID: 21750861
[TBL] [Abstract][Full Text] [Related]
4. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of 4E-BP1 sensitizes U87 glioblastoma xenograft tumors to irradiation by decreasing hypoxia tolerance.
Dubois L; Magagnin MG; Cleven AH; Weppler SA; Grenacher B; Landuyt W; Lieuwes N; Lambin P; Gorr TA; Koritzinsky M; Wouters BG
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1219-27. PubMed ID: 19251093
[TBL] [Abstract][Full Text] [Related]
6. Putative role of the mTOR/4E-BP1 signaling pathway in the carcinogenesis and progression of gastric cardiac adenocarcinoma.
Yang HY; Xue LY; Xing LX; Wang J; Wang JL; Yan X; Zhang XH
Mol Med Rep; 2013 Feb; 7(2):537-42. PubMed ID: 23229050
[TBL] [Abstract][Full Text] [Related]
7. mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio.
Alain T; Sonenberg N; Topisirovic I
Oncotarget; 2012 Dec; 3(12):1491-2. PubMed ID: 23455427
[No Abstract] [Full Text] [Related]
8. Prognostic significance of expression of eukaryotic initiation factor 4E and 4E binding protein 1 in patients with pathological stage I invasive lung adenocarcinoma.
Seki N; Takasu T; Sawada S; Nakata M; Nishimura R; Segawa Y; Shibakuki R; Hanafusa T; Eguchi K
Lung Cancer; 2010 Dec; 70(3):329-34. PubMed ID: 20621385
[TBL] [Abstract][Full Text] [Related]
9. Different roles for the TOS and RAIP motifs of the translational regulator protein 4E-BP1 in the association with raptor and phosphorylation by mTOR in the regulation of cell size.
Eguchi S; Tokunaga C; Hidayat S; Oshiro N; Yoshino K; Kikkawa U; Yonezawa K
Genes Cells; 2006 Jul; 11(7):757-66. PubMed ID: 16824195
[TBL] [Abstract][Full Text] [Related]
10. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M
Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159
[TBL] [Abstract][Full Text] [Related]
11. Anti-oncogenic potential of the eIF4E-binding proteins.
Martineau Y; Azar R; Bousquet C; Pyronnet S
Oncogene; 2013 Feb; 32(6):671-7. PubMed ID: 22508483
[TBL] [Abstract][Full Text] [Related]
12. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
[TBL] [Abstract][Full Text] [Related]
13. Snail determines the therapeutic response to mTOR kinase inhibitors by transcriptional repression of 4E-BP1.
Wang J; Ye Q; Cao Y; Guo Y; Huang X; Mi W; Liu S; Wang C; Yang HS; Zhou BP; Evers BM; She QB
Nat Commun; 2017 Dec; 8(1):2207. PubMed ID: 29263324
[TBL] [Abstract][Full Text] [Related]
14. Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer.
Satheesha S; Cookson VJ; Coleman LJ; Ingram N; Madhok B; Hanby AM; Suleman CA; Sabine VS; Macaskill EJ; Bartlett JM; Dixon JM; McElwaine JN; Hughes TA
Mol Cancer; 2011 Feb; 10():19. PubMed ID: 21320304
[TBL] [Abstract][Full Text] [Related]
15. Translation control during prolonged mTORC1 inhibition mediated by 4E-BP3.
Tsukumo Y; Alain T; Fonseca BD; Nadon R; Sonenberg N
Nat Commun; 2016 Jun; 7():11776. PubMed ID: 27319316
[TBL] [Abstract][Full Text] [Related]
16. Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation.
Cope CL; Gilley R; Balmanno K; Sale MJ; Howarth KD; Hampson M; Smith PD; Guichard SM; Cook SJ
J Cell Sci; 2014 Feb; 127(Pt 4):788-800. PubMed ID: 24363449
[TBL] [Abstract][Full Text] [Related]
17. The mTOR Targets 4E-BP1/2 Restrain Tumor Growth and Promote Hypoxia Tolerance in PTEN-driven Prostate Cancer.
Ding M; Van der Kwast TH; Vellanki RN; Foltz WD; McKee TD; Sonenberg N; Pandolfi PP; Koritzinsky M; Wouters BG
Mol Cancer Res; 2018 Apr; 16(4):682-695. PubMed ID: 29453322
[TBL] [Abstract][Full Text] [Related]
18. Identification and function of the second eIF4E-binding region in N-terminal domain of eIF4G: comparison with eIF4E-binding protein.
Umenaga Y; Paku KS; In Y; Ishida T; Tomoo K
Biochem Biophys Res Commun; 2011 Oct; 414(3):462-7. PubMed ID: 21964297
[TBL] [Abstract][Full Text] [Related]
19. p-mTOR, p-4EBP-1 and eIF4E expression in canine prostatic carcinoma.
Rivera-Calderón LG; Fonseca-Alves CE; Kobayashi PE; Carvalho M; Vasconcelos RO; Laufer-Amorim R
Res Vet Sci; 2019 Feb; 122():86-92. PubMed ID: 30476726
[TBL] [Abstract][Full Text] [Related]
20. Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond.
Pettersson F; Del Rincon SV; Miller WH
Expert Opin Ther Targets; 2014 Sep; 18(9):1035-48. PubMed ID: 25004955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
